Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

2

Revenue 2017

Revlimid

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Revlimid was produced by Celgene.

Amgen's Kyprolis wins new indication in Europe

Amgen's Kyprolis wins new indication in Europe Last November it was approved in Europe in combination with Celgene's Revlimid (lenalidomide) as well as dexamethasone in this therapy area, after receiving the green light in the US more

J&J gets European OK for myeloma therapy Darzalex

J&J gets European OK for myeloma therapy Darzalex s Velcade (bortezomib) and an immunomodulatory agent like Celgene's Revlimid (lenalidomide).

BMS gets two new cancer approvals in Europe

BMS gets two new cancer approvals in Europe Empliciti (elotuzumab) has been approved by the European Medicines Agency (EMA) as a second-line therapy for myeloma in combination with Celgene's Revlimid (lenalidomide) and dexamethasone. ... to Revlimid and dexamethasone alone, with a trend in favour

GSK gene therapy tops CHMP recommendations

GSK gene therapy tops CHMP recommendations immunomodulatory agent like Celgene's Revlimid (lenalidomide).

Amgen's roll-out of myeloma drug Kyprolis reaches UK

Amgen's roll-out of myeloma drug Kyprolis reaches UK Kyprolis is the first irreversible proteasome inhibitor to reach the UK market and is indicated for use in combination with Celgene's multiple myeloma therapy Revlimid (lenalidomide) and dexamethasone to treat ... This showed that patients treated with

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics